{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T18:24:01Z","timestamp":1787595841261,"version":"build-2736575974"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100007194","name":"Wenzhou Municipal Science and Technology Bureau","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007194","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","amjmedsci.org","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.amjms.2024.08.025","type":"journal-article","created":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T19:04:47Z","timestamp":1725390287000},"page":"189-196","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["CT-based body composition parameters predict the loss of response to infliximab in patients with Crohn's disease"],"prefix":"10.1016","volume":"369","author":[{"given":"Shaotang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouliang","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yini","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.amjms.2024.08.025_bib0001","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph14030238","article-title":"The disease burden and clinical characteristics of inflammatory bowel disease in the Chinese population: a systematic review and meta-analysis","volume":"14","author":"Li","year":"2017","journal-title":"Int J Environ Res Public Health"},{"issue":"10114","key":"10.1016\/j.amjms.2024.08.025_bib0002","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies","volume":"390","author":"Ng","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.amjms.2024.08.025_bib0003","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/7247238","article-title":"A Comprehensive review and update on the pathogenesis of inflammatory bowel disease","volume":"2019","author":"Guan","year":"2019","journal-title":"J Immunol Res"},{"issue":"4","key":"10.1016\/j.amjms.2024.08.025_bib0004","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/apt.14852","article-title":"Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn's disease","volume":"48","author":"Singh","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.amjms.2024.08.025_bib0005","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","article-title":"ECCO guidelines on therapeutics in Crohn's disease: medical treatment","volume":"14","author":"Torres","year":"2020","journal-title":"J Crohns Colitis"},{"issue":"Suppl 3","key":"10.1016\/j.amjms.2024.08.025_bib0006","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","article-title":"British society of gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults","volume":"68","author":"Lamb","year":"2019","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.amjms.2024.08.025_bib0007","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/MCG.0b013e3181ebaef9","article-title":"Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose \u201cescalation\u201d in patients losing response","volume":"45","author":"Chaparro","year":"2011","journal-title":"J Clin Gastroenterol"},{"issue":"2","key":"10.1016\/j.amjms.2024.08.025_bib0008","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.crohns.2011.07.011","article-title":"Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: a large single centre experience","volume":"6","author":"Sprakes","year":"2012","journal-title":"J Crohns Colitis"},{"issue":"10","key":"10.1016\/j.amjms.2024.08.025_bib0009","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1097\/MIB.0000000000001172","article-title":"Serum interleukin 9 levels predict disease severity and the clinical efficacy of infliximab in patients with Crohn's disease","volume":"23","author":"Feng","year":"2017","journal-title":"Inflamm Bowel Dis"},{"issue":"8","key":"10.1016\/j.amjms.2024.08.025_bib0010","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1093\/ibd\/izz012","article-title":"Actual anti-TNF trough levels relate to serum IL-10 in drug-responding patients with Crohn's disease","volume":"25","author":"Zapater","year":"2019","journal-title":"Inflamm Bowel Dis"},{"issue":"10","key":"10.1016\/j.amjms.2024.08.025_bib0011","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0204632","article-title":"Factors predicting the therapeutic response to infliximab during maintenance therapy in Japanese patients with Crohn's disease","volume":"13","author":"Matsuoka","year":"2018","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.amjms.2024.08.025_bib0012","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1097\/MIB.0b013e31829cf401","article-title":"Increased body mass index is associated with earlier time to loss of response to infliximab in patients with inflammatory bowel disease","volume":"19","author":"Harper","year":"2013","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"10.1016\/j.amjms.2024.08.025_bib0013","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1007\/s00330-019-06573-2","article-title":"Imaging of sarcopenia: old evidence and new insights","volume":"30","author":"Albano","year":"2020","journal-title":"Eur Radiol"},{"issue":"10","key":"10.1016\/j.amjms.2024.08.025_bib0014","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1038\/s41430-021-00857-x","article-title":"Combination of sarcopenia and high visceral fat predict poor outcomes in patients with Crohn's disease","volume":"75","author":"Boparai","year":"2021","journal-title":"Eur J Clin Nutr"},{"issue":"10","key":"10.1016\/j.amjms.2024.08.025_bib0015","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1016\/j.clnu.2020.01.001","article-title":"Sarcopenia and visceral obesity assessed by computed tomography are associated with adverse outcomes in patients with Crohn's disease","volume":"39","author":"Grillot","year":"2020","journal-title":"Clin Nutr"},{"issue":"9","key":"10.1016\/j.amjms.2024.08.025_bib0016","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1093\/annonc\/mdx271","article-title":"Forcing the vicious circle: sarcopenia increases toxicity, decreases response to chemotherapy and worsens with chemotherapy","volume":"28","author":"Bozzetti","year":"2017","journal-title":"Ann Oncol"},{"issue":"16","key":"10.1016\/j.amjms.2024.08.025_bib0017","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.1158\/0008-5472.CAN-18-0125","article-title":"LIFEx: a freeware for radiomic feature calculation in multimodality imaging to accelerate advances in the characterization of tumor heterogeneity","volume":"78","author":"Nioche","year":"2018","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.amjms.2024.08.025_bib0018","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1139\/H08-075","article-title":"A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care","volume":"33","author":"Mourtzakis","year":"2008","journal-title":"Appl Physiol Nutr Metab"},{"issue":"9","key":"10.1016\/j.amjms.2024.08.025_bib0019","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1080\/00365521.2021.1939411","article-title":"A random forest model predicts responses to infliximab in Crohn's disease based on clinical and serological parameters","volume":"56","author":"Li","year":"2021","journal-title":"Scand J Gastroenterol"},{"issue":"7","key":"10.1016\/j.amjms.2024.08.025_bib0020","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S1470-2045(08)70153-0","article-title":"Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study","volume":"9","author":"Prado","year":"2008","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.amjms.2024.08.025_bib0021","doi-asserted-by":"crossref","first-page":"e00233","DOI":"10.14309\/ctg.0000000000000233","article-title":"The effect of adiposity on anti-tumor necrosis factor-alpha levels and loss of response in Crohn's disease patients","volume":"11","author":"Lim","year":"2020","journal-title":"Clin Transl Gastroenterol"},{"issue":"8","key":"10.1016\/j.amjms.2024.08.025_bib0022","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s40262-017-0627-0","article-title":"Clinical pharmacokinetics and pharmacodynamics of infliximab in the treatment of inflammatory bowel disease","volume":"57","author":"Hemperly","year":"2018","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"10.1016\/j.amjms.2024.08.025_bib0023","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s00228-009-0718-4","article-title":"Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis","volume":"65","author":"Fasanmade","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.amjms.2024.08.025_bib0024","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1097\/MIB.0000000000000212","article-title":"Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study","volume":"20","author":"Dotan","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.amjms.2024.08.025_bib0025","article-title":"Role of the CCL2-CCR2 axis in cardiovascular disease: pathogenesis and clinical implications","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"issue":"12","key":"10.1016\/j.amjms.2024.08.025_bib0026","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1097\/MIB.0b013e3182a77b41","article-title":"Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study","volume":"19","author":"Paul","year":"2013","journal-title":"Inflamm Bowel Dis"},{"issue":"9","key":"10.1016\/j.amjms.2024.08.025_bib0027","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/apt.14293","article-title":"The body composition profile is associated with response to anti-TNF therapy in Crohn's disease and may offer an alternative dosing paradigm","volume":"46","author":"Ding","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.amjms.2024.08.025_bib0028","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1111\/cts.13621","article-title":"Sarcopenia assessed by computed tomography or magnetic resonance imaging is associated with the loss of response to biologic therapies in adult patients with Crohn's disease","volume":"16","author":"Liu","year":"2023","journal-title":"Clin Transl Sci"},{"issue":"5","key":"10.1016\/j.amjms.2024.08.025_bib0029","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/apt.13058","article-title":"Infliximab reverses inflammatory muscle wasting (sarcopenia) in Crohn's disease","volume":"41","author":"Subramaniam","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.amjms.2024.08.025_bib0030","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s13244-021-01121-3","article-title":"Magnetic resonance imaging-based body composition is associated with nutritional and inflammatory status: a longitudinal study in patients with Crohn's disease","volume":"12","author":"Zhou","year":"2021","journal-title":"Insights Imaging"},{"issue":"1","key":"10.1016\/j.amjms.2024.08.025_bib0031","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1152\/jappl.2000.89.1.81","article-title":"Skeletal muscle mass and distribution in 468 men and women aged 18-88 yr","volume":"89","author":"Janssen","year":"2000","journal-title":"J Appl Physiol (1985)"},{"issue":"4","key":"10.1016\/j.amjms.2024.08.025_bib0032","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/BF03324517","article-title":"Body composition changes in stable-weight elderly subjects: the effect of sex","volume":"15","author":"Zamboni","year":"2003","journal-title":"Aging Clin Exp Res"},{"key":"10.1016\/j.amjms.2024.08.025_bib0033","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/978-3-319-70178-3_9","article-title":"Sex differences in muscle wasting","volume":"1043","author":"Anderson","year":"2017","journal-title":"Adv Exp Med Biol"},{"issue":"3","key":"10.1016\/j.amjms.2024.08.025_bib0034","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/ecco-jcc\/jjx138","article-title":"Changes in disease behaviour and location in patients with Crohn's disease after seven years of follow-up: a Danish population-based inception cohort","volume":"12","author":"Lo","year":"2018","journal-title":"J Crohns Colitis"},{"issue":"10-11","key":"10.1016\/j.amjms.2024.08.025_bib0035","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1080\/00365521.2018.1503709","article-title":"Clinical course in Crohn's disease: factors associated with behaviour change and surgery","volume":"53","author":"Arieira","year":"2018","journal-title":"Scand J Gastroenterol"},{"issue":"974","key":"10.1016\/j.amjms.2024.08.025_bib0036","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1259\/bjr\/80083156","article-title":"Whole-body adipose tissue analysis: comparison of MRI, CT and dual energy X-ray absorptiometry","volume":"82","author":"Kullberg","year":"2009","journal-title":"Br J Radiol"},{"issue":"9","key":"10.1016\/j.amjms.2024.08.025_bib0037","doi-asserted-by":"crossref","DOI":"10.3390\/nu10091192","article-title":"Obesity in inflammatory bowel disease: gains in adiposity despite high prevalence of myopenia and osteopenia","volume":"10","author":"Bryant","year":"2018","journal-title":"Nutrients"},{"issue":"2","key":"10.1016\/j.amjms.2024.08.025_bib0038","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1590\/s0004-2803.201800000-25","article-title":"Visceral fat is increased in individuals with Crohn's disease: a comparative analysis with healthy controls","volume":"55","author":"Magro","year":"2018","journal-title":"Arq Gastroenterol"},{"issue":"6","key":"10.1016\/j.amjms.2024.08.025_bib0039","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/DCR.0000000000001074","article-title":"Visceral fat is associated with mucosal healing of infliximab treatment in Crohn's disease","volume":"61","author":"Shen","year":"2018","journal-title":"Dis Colon Rectum"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962924014411?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962924014411?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T04:15:47Z","timestamp":1738124147000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962924014411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S0002962924014411"],"URL":"https:\/\/doi.org\/10.1016\/j.amjms.2024.08.025","relation":{},"ISSN":["0002-9629"],"issn-type":[{"value":"0002-9629","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CT-based body composition parameters predict the loss of response to infliximab in patients with Crohn's disease","name":"articletitle","label":"Article Title"},{"value":"The American Journal of the Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjms.2024.08.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}